New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus, Which Has Been Trapped In Troubled Financial Seas

BEIJING - A new vaccine joint venture with the United Kingdom's GlaxoSmithKline could become a lifesaver for the Chinese biologics outfit Shenzhen Neptunus Interlong Bio-Technique Co., which has been fighting to stay afloat amid a maelstrom of earnings losses, staff layoffs and a partial halt in production